CORRIGENDUM
Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P, On Behalf of the DERIVE Study Investigators. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes, Obesity and Metabolism 2018; 20(11): 2532–2540. https://doi.org/10.1111/dom.13413
In the article ‘Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study’, the ‘total’ values in Table 3 are incorrect, due to an overcounting error in the number of patients experiencing hypoglycaemic events. As some patients may have had both ‘minor’ and ‘other’ events, a summation of both categories to give the ‘total’ value was incorrect. The corrected values are shown below:
Dapagliflozin 10 mg (N = 160) | Placebo (N = 161) | |||
---|---|---|---|---|
Patients, n (%) | Events, n | Patients, n (%) | Events, n | |
Total | 17 (10.6) | 44 | 18 (11.2) | 62 |
Major | 0 | 0 | 0 | 0 |
Minor | 12 (7.5) | 34 | 16 (9.9) | 53 |
Other |